PRDS · Pardes Biosciences, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Revenue | $0 | $0 |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| R&D | $70.35M | $28.15M |
| SG&A | $29.47M | $10.34M |
| Total Operating Expenses | $99.82M | $38.49M |
| D&A | - | - |
| Operating Income | - | $38.49M |
| Interest Expense | - | - |
| Income Tax | $0 | $0 |
| Net Income | ($96.63M) | ($38.52M) |
| EPS - Basic | ($10.13) | - |
| EPS - Diluted | ($10.13) | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Cash & Equivalents | $59.28M | $268.68M |
| Accounts Receivable | - | - |
| Inventory | - | - |
| Accounts Payable | $4.93M | $2.38M |
| Current Assets | $200.40M | $275.26M |
| Total Assets | $200.62M | $275.26M |
| Current Liabilities | $20.43M | $8.96M |
| Long-term Debt | - | - |
| Total Liabilities | $20.43M | $8.96M |
| Stockholders' Equity | $180.20M | $0 |
| Retained Earnings | ($148.16M) | ($51.52M) |
Cash Flow
| Line item | FY 2022 | FY 2021 |
|---|---|---|
| Operating Cash Flow | ($71.98M) | ($36.92M) |
| Investing Cash Flow | $0 | - |
| Financing Cash Flow | ($397.0K) | $302.19M |
| CapEx | - | - |
| Free Cash Flow | - | - |
Ratios
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Profitability | ||
| Gross margin | - | - |
| Operating margin | - | - |
| EBITDA margin | - | - |
| Net margin | - | - |
| Free cash flow margin | - | - |
| FCF / Net income | - | - |
| R&D / Revenue | - | - |
| SG&A / Revenue | - | - |
| Effective tax rate | - | - |
| Return on assets | -48.2% | -14.0% |
| Return on equity | -53.6% | - |
| Return on invested capital | - | - |
| Liquidity | ||
| Current ratio | 9.81 | 30.70 |
| Quick ratio | 9.81 | 30.70 |
| Cash ratio | 2.90 | 29.97 |
| Leverage | ||
| Debt / Equity | - | - |
| Debt / Assets | - | - |
| Debt / EBITDA | - | - |
| Interest coverage | - | - |
| Equity multiplier | 1.11 | - |
| Liabilities / Assets | 0.10 | 0.03 |
| Efficiency | ||
| Asset turnover | 0.00 | 0.00 |
| Inventory turnover | - | - |
| Days sales outstanding | - | - |
| Days inventory outstanding | - | - |
| Days payable outstanding | - | - |
| Cash conversion cycle | - | - |
| Valuation | ||
| P / E | - | - |
| P / B | - | - |
| P / S | - | - |
| EV / EBITDA | - | - |
| Growth | ||
| Revenue growth (YoY) | - | - |
| Revenue CAGR (3y) | - | - |
| Revenue CAGR (5y) | - | - |
| Gross profit growth (YoY) | - | - |
| Operating income growth (YoY) | - | - |
| Net income growth (YoY) | -150.9% | - |
| EPS growth (YoY) | - | - |
| EPS CAGR (3y) | - | - |
| EPS CAGR (5y) | - | - |
| FCF growth (YoY) | - | - |
| FCF CAGR (5y) | - | - |
| Book value growth (YoY) | - | - |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- -No share dilution
- -Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing PARDES BIOSCIENCES against the 5 most active filers in the same SIC group.